N-Type Calcium Channel Selective Benzenesulfonamides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current calcium channel blockers, particularly for N-type channels, often lack selectivity over L-type channels, leading to potential hypotensive effects and a need for antagonists that specifically target N-type channels to avoid these effects.
Innovation Solution
Development of azetidinyl, pyrrolidinyl, and hexahydroazepinyl benzenesulfonamides represented by Formula I, along with their pharmaceutically acceptable salts, prodrugs, and solvates, which act as selective N-type calcium channel blockers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective calcium channel blockers are used to treat disorders with excessive calcium channel activity, then calcium influx is reduced, but hypotensive effects occur due to L-type channel inhibition
Solution Approach 1:
The invention segments the calcium channel blocking action by developing compounds that selectively inhibit N-type calcium channels while sparing L-type channels. This is achieved through specific molecular structures (Formula I compounds with particular substituent patterns) that confer selectivity for N-type channels, thereby providing therapeutic efficacy for pain and neuroprotection without the hypotensive side effects associated with L-type channel blockade
Solution Approach 2:
The invention applies local quality by designing compounds with specific structural features (substituents R1-R6 at defined positions) that create localized interactions with N-type calcium channels. The benzenesulfonamide core with specific heterocyclic substituents (azetidinyl, pyrrolidinyl, piperidinyl, or hexahydroazepinyl) provides localized binding characteristics that distinguish N-type from L-type channels, enabling selective inhibition
2Reliability
If L-type calcium channels are blocked to achieve neuroprotection, then neuronal damage is reduced, but arterial pressure drops profoundly
Solution Approach 1:
The invention segments the calcium channel family into targetable subtypes by developing N-type selective blockers. The compounds of Formula I are designed to interact specifically with N-type channel residues (such as Phe746, Phe747, and Phe748 in the III-IV linker region) through hydrophobic interactions, while avoiding L-type channel binding sites, thus providing neuroprotection without affecting blood pressure regulation
Solution Approach 2:
The invention introduces N-type selective calcium channel blockers as intermediary agents that provide neuroprotection through a different mechanism than L-type blockers. These compounds act as selective intermediaries that block N-type channels in the nervous system (providing neuroprotection and analgesia) without blocking L-type channels in the heart and blood vessels (avoiding hypotension)
3Reliability
If N-type calcium channels are blocked to achieve analgesia, then pain transmission is inhibited, but selectivity over other channel types must be maintained to avoid side effects
Solution Approach 1:
The invention applies local quality by designing compounds with specific structural features (substituents R1-R6 at defined positions) that create localized interactions with N-type calcium channels. The benzenesulfonamide core with specific heterocyclic substituents (azetidinyl, pyrrolidinyl, piperidinyl, or hexahydroazepinyl) provides localized binding characteristics that distinguish N-type from L-type channels, enabling selective inhibition
Solution Approach 2:
The invention employs parameter changes by systematically varying molecular parameters (substituent types, positions, and configurations in Formula I) to optimize selectivity for N-type channels. By adjusting parameters such as the heterocyclic ring size (4-7 membered rings), substituent positions (R1-R6), and stereochemistry, the compounds achieve high N-type selectivity while maintaining potent analgesic activity
Data Source
AI summary
The invention relates to azetidinyl, pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R1, R2, R3, Z and q are defined as set forth in the specification. The invention is also directed to the use compounds of Formula I to treat a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.